Development of in vivo gene therapy using exosomes loading immunomodulatory molecules
Project/Area Number |
18H02562
|
Research Category |
Grant-in-Aid for Scientific Research (B)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Review Section |
Basic Section 47020:Pharmaceutical analytical chemistry and physicochemistry-related
|
Research Institution | Kyoto University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
高橋 有己 京都大学, 薬学研究科, 准教授 (00547870)
|
Project Period (FY) |
2018-04-01 – 2021-03-31
|
Project Status |
Completed (Fiscal Year 2020)
|
Budget Amount *help |
¥17,420,000 (Direct Cost: ¥13,400,000、Indirect Cost: ¥4,020,000)
Fiscal Year 2020: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2019: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2018: ¥7,410,000 (Direct Cost: ¥5,700,000、Indirect Cost: ¥1,710,000)
|
Keywords | エキソソーム / ルシフェラーゼ / 免疫療法 / サイトカイン / 免疫 / 内因性 |
Outline of Final Research Achievements |
In this study, we analyzed the behavior of endogenous exosomes and developed a method to attach immunoregulatory molecules to exosomes in order to develop in vivo gene immunotherapy using endogenous exosomes produced in the body. We focused on blood exosomes as endogenous exosomes, and succeeded in establishing a method to collect and label them. We selected NBD peptide, an NF-κB inhibitory peptide, as an immunoregulatory molecule, and succeeded in developing an efficient method for loading NBD peptide into exosomes. The NBD peptide-loaded exosomes showed a high anti-inflammatory effect. In conclusion, we have succeeded in establishing the basis for in vivo gene immunotherapy using endogenous exosomes.
|
Academic Significance and Societal Importance of the Research Achievements |
細胞から産生される粒子径100nm程度の膜小胞であるエキソソームは、細胞間で物質輸送を行う輸送担体であり、その生理機能の解明とそれを利用した治療法の開発が期待される。本研究では、体内におけるエキソソームの挙動の解明と治療用分子の搭載方法の確立に成功したが、これはエキソソームの生理機能の解明を目的とした研究並びに治療法の開発において重要な知見を提供するものである。
|
Report
(4 results)
Research Products
(12 results)